卡波西肉瘤相关疱疹病毒感染
中文名称
通路描述
卡波西肉瘤相关疱疹病毒(KSHV),也称为人类疱疹病毒8(HHV-8),是最近发现的人类肿瘤病毒,与卡波西肉瘤(KS)、原发性浆液性淋巴瘤(PEL)和多中心 Castleman 病(MCD)的发病机制相关。与其他所有疱疹病毒一样,KSHV具有两种生命周期模式:潜伏和裂解复制,其特征是病毒基因表达的模式。在潜伏期表达的基因(LANA、v-cyclin、v-FLIP、Kaposins A、B和C以及病毒miRNAs)主要被认为有助于在宿主体内建立长期潜伏状态,并抵抗宿主的先天免疫和适应性免疫监控机制。在裂解复制期间表达的病毒蛋白包括强大的信号分子,如vGPCR、vIL6、vIRFs、vCCLs、K1和K15,这些已被实验证明与KS病变中观察到的血管生成和炎症表型相关。其中一些潜伏病毒和裂解病毒蛋白已知可转化宿主细胞,将KSHV与严重人类恶性肿瘤的发展联系起来。
英文描述
Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8), is the most recently identified human tumor virus, and is associated with the pathogenesis of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Multicentric Castleman's disease (MCD). Like all other herpesviruses, KSHV displays two modes of life cycle, latency and lytic replication, which are characterized by the patterns of viral gene expression. Genes expressed in latency (LANA, v-cyclin, v-FLIP, Kaposins A, B and C and viral miRNAs) are mainly thought to facilitate the establishment of life long latency in its host and survival against the host innate, and adaptive immune surveillance mechanisms. Among the viral proteins shown to be expressed during lytic replication are potent signaling molecules such as vGPCR, vIL6, vIRFs, vCCLs, K1 and K15, which have been implicated experimentally in the angiogenic and inflammatory phenotype observed in KS lesions. Several of these latent viral and lytic proteins are known to transform host cells, linking KSHV with the development of severe human malignancies.
所含基因
196 个基因
AKT1
AKT2
AKT3
ANGPT2
ATG14
ATG3
BAK1
BAX
BECN1
BECN2
BID
C3
CALM1
CALM2
CALM3
CALML3
CALML4
CALML5
CALML6
CASP3
CASP8
CASP9
CCND1
CCR1
CCR3
CCR4
CCR5
CCR8
CD200R1
CD200R1L
CD86
CDK4
CDK6
CDKN1A
CHUK
CLEC2B
CREB1
CREBBP
CSF2
CTNNB1
CXCL1
CXCL2
CXCL3
CXCL8
CYCS
E2F1
E2F2
E2F3
EIF2AK2
EP300
FADD
FAS
FGF2
FOS
GNB1
GNB2
GNB3
GNB4
GNB5
GNG10
GNG11
GNG12
GNG13
GNG2
GNG3
GNG4
GNG5
GNG7
GNG8
GNGT1
GNGT2
GSK3B
HCK
HIF1A
HLA-A
HLA-B
HLA-C
HLA-E
HLA-F
HLA-G
HRAS
ICAM1
IFNA1
IFNA10
IFNA13
IFNA14
IFNA16
IFNA17
IFNA2
IFNA21
IFNA4
IFNA5
IFNA6
IFNA7
IFNA8
IFNAR1
IFNAR2
IFNB1
IFNGR1
IKBKB
IKBKE
IKBKG
IL6
IL6ST
IRF3
IRF7
IRF9
ITPR1
ITPR2
ITPR3
JAK1
JAK2
JUN
KRAS
LEF1
LYN
MAP1LC3A
MAP1LC3B
MAP1LC3B2
MAP1LC3BP1
MAP1LC3C
MAP2K1
MAP2K2
MAP2K4
MAP2K6
MAP2K7
MAPK1
MAPK10
MAPK11
MAPK12
MAPK13
MAPK14
MAPK3
MAPK8
MAPK9
MAPKAPK2
MICA
MICB
MTOR
MYC
NFATC1
NFATC2
NFATC3
NFATC4
NFKB1
NFKBIA
NRAS
P3R3URF-PIK3R3
PDGFB
PIK3C3
PIK3CA
PIK3CB
PIK3CD
PIK3CG
PIK3R1
PIK3R2
PIK3R3
PIK3R5
PIK3R6
PLCG1
PLCG2
PPP3CA
PPP3CB
PPP3CC
PPP3R1
PPP3R2
PREX1
PTGS2
RAC1
RAF1
RB1
RCAN1
RELA
RPS27A
SRC
STAT1
STAT2
STAT3
SYK
TBK1
TCF7
TCF7L1
TCF7L2
TICAM1
TLR3
TNFRSF1A
TP53
TRADD
TRAF2
TRAF3
TYK2
UBA52
UBB
UBC
VEGFA
ZFP36